IntelGenx Corp. (IGXT) Receives FDA Approval for High Dose Anti-Depressant CPI-300
IntelGenx Corp. today announced with excitement that the U.S. Food and Drug Administration (FDA) has approved its lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. According to the company’s press release, CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA. "This is a defining moment for IntelGenx, as we have now clearly demonstrated our ability to independently take a product through development to regulatory approval," stated Dr. Horst G. Zerbe, President and Chief Executive Officer of…